Ergoteles’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ergoteles’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$14.1M	Buy	121,905 +25,000	+26%	+$2.69M	20.67%	2
2023 Q2	$9.97M	Sell	96,905 -17,269	-15%	-$1.82M	0.48%	33
2023 Q1	$12.5M	Buy	114,174 +30,114	+36%	+$3.33M	0.49%	38
2022 Q4	$9.57M	Buy	84,060 +60,648	+259%	+$5.04M	0.35%	66
2022 Q3	$1.45M	Buy	+23,412	New	+$1.64M	0.05%	363
2022 Q2	–	Sell	-8,161	Closed	-$859K	–	2170
2022 Q1	$859K	Buy	+8,161	New	+$795K	0.03%	483
2021 Q3	–	Sell	-46,562	Closed	-$4.36M	–	1891
2021 Q2	$4.36M	Buy	+46,562	New	+$4.28M	0.1%	246
2020 Q4	–	Sell	-152,643	Closed	-$11.9M	–	1005
2020 Q3	$11.9M	Buy	+152,643	New	+$10.5M	1.57%	12

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ergoteles's HZNP Position: Q3 2023 in Review

Ergoteles increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 26% in Q3 2023, buying an estimated $2.69M and bringing the position to 121,905 shares worth $14.1M. The position accounts for 20.67% of the portfolio, ranked #2.

Ergoteles first reported a position in HZNP in Q3 2020 and has held it in 8 quarters since. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Ergoteles held 121,905 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $14.1M as of Q3 2023.
Ergoteles bought 25,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $2.69M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 20.67% of Ergoteles's portfolio in Q3 2023, its #2 holding.
Ergoteles first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and has held it in 8 quarters since.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.